Home fashion/lifestyle Boots launches medical cannabis prescription in ‘UK first’

Boots launches medical cannabis prescription in ‘UK first’

0
3

It will be offered as a treatment option “where conventional treatments have not provided adequate symptom relief.”

Boots will start prescribing medical cannabis to those with specific health conditions. It becomes the first pharmacy on the UK high street to do so.

SureLeaf is just the latest specialist service to be launched by the British stalwart that operates approximately 1,800 stores across Great Britain, making it the largest health and beauty chain in the country.

It will be offered as a treatment option “where conventional treatments have not provided adequate symptom relief”. Operating as a private healthcare option, it will be available for those with eligible chronic pain conditions, general anxiety disorder and insomnia.

Patients aged 25 years-old and over can begin their assessment online through Boots’ Online Doctor service. A clinical team will review suitability before offering a video consultation with a relevant medical specialist consultant.

Designed to help manage symptoms and “improve quality of life”, any proposed medical cannabis prescription will be independently reviewed by a multidisciplinary clinical team that includes a second independent consultant, before treatment begins.

Patients will have had to previously explored conventional methods of pain relief without any success to be eligible. Once on SureLeaf, they will be provided with ongoing clinical support and monitoring by Boots’ pharmacies.

This will include receiving an initial review after 28 days, which will then be followed by a review every three months. Validated questionnaires will be used throughout treatment to assess relevant areas including quality of life, pain, anxiety, sleep and mood, helping clinicians monitor the effectiveness of treatment.

Jamie Kerruish, Chief Healthcare Officer, Boots, said: “At Boots, we’re committed to making healthcare more accessible and helping people find the right support for their individual needs. Millions of people live with ongoing pain and for some, conventional treatments do not provide adequate symptom relief.

“This can have a significant impact on everyday life, from working and sleeping well to spending time with family and doing the things they enjoy. Medical cannabis is a specialist area of healthcare and, through SureLeaf, we’re giving eligible patients another treatment option to consider, supported by clinical expertise and robust ongoing care.

“Ultimately, it’s about helping people explore appropriate options that could help them better manage their symptoms and improve their quality of life.”

Medical cannabis was legalised in the UK in 2018. However, it has previously only been available through specialist doctors, healthcare services. They can also be found online, although quality and content is often unknown, meaning they could be illegal.

With the launch of Boots’ SureLeaf service, it offers a safer and more accessible option for those who have tried conventional pain relieving methods in the past. The retailer is also supporting the launch with a collaborative research programme alongside the University of Nottingham.

This will build-on the existing real-world evidence and understanding of medical cannabis in chronic pain management. The service itself will also come with a few prescription fees, with a one-month trial costing £89 and an annual plan priced at £99.

Jamie Kerruish, Chief Healthcare Officer, Boots, said: “At Boots, we’re committed to making healthcare more accessible and helping people find the right support for their individual needs. Millions of people live with ongoing pain and for some, conventional treatments do not provide adequate symptom relief.

Dr David Gwynne, Medical Director, Boots Online Doctor, said: “Medical cannabis is not appropriate for everyone and prescribing decisions need to be made carefully on an individual patient basis.

Article continues below

“SureLeaf has therefore been designed with strong clinical safeguards and specialist oversight at every stage, so treatment is only considered for patients where it is clinically appropriate. Our priority is to ensure patients receive responsible, clinically led care, from their initial specialist assessment through to ongoing monitoring and review once treatment begins.”

Disclaimer : This story is auto aggregated by a computer programme and has not been created or edited by DOWNTHENEWS. Publisher: www.dailyrecord.co.uk